KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medpace Holdings (MEDP) EBIT Margin (2016 - 2026)

Medpace Holdings filings provide 12 years of EBIT Margin readings, the most recent being 20.03% for Q1 2026.

  • On a quarterly basis, EBIT Margin fell 30.0% to 20.03% in Q1 2026 year-over-year; TTM through Mar 2026 was 21.02%, a 14.0% decrease, with the full-year FY2025 number at 21.14%, down 5.0% from a year prior.
  • EBIT Margin hit 20.03% in Q1 2026 for Medpace Holdings, down from 21.63% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 23.37% in Q4 2024 to a low of 17.01% in Q2 2023.
  • Median EBIT Margin over the past 5 years was 20.03% (2026), compared with a mean of 19.82%.
  • Biggest five-year swings in EBIT Margin: crashed -304bps in 2023 and later surged 585bps in 2024.
  • Medpace Holdings' EBIT Margin stood at 19.39% in 2022, then dropped by -10bps to 17.52% in 2023, then soared by 33bps to 23.37% in 2024, then dropped by -7bps to 21.63% in 2025, then fell by -7bps to 20.03% in 2026.
  • The last three reported values for EBIT Margin were 20.03% (Q1 2026), 21.63% (Q4 2025), and 21.49% (Q3 2025) per Business Quant data.